# Inductive Bio

> Inductive Bio is a New York-based AI company building a machine learning platform that predicts how small-molecule drugs will behave in the body before they are ever synthesized. By training models on a pre-competitive data consortium shared across biopharma teams, its Beacon models, Compass software, and Indy chemistry assistant help medicinal chemists nominate better development candidates faster - reducing the costly 'whack-a-mole' of balancing potency against ADMET properties in preclinical drug discovery.

- **Founded:** 2023
- **Headquarters:** New York, New York, United States
- **Founders:** Josh Haimson (Co-founder & CEO), Ben Birnbaum (Co-founder & CTO)
- **Team size:** ~37 employees (LinkedIn); small core team described as 'small but mighty'
- **Products:** Beacon-1, Compass, Indy, ADME-One
- **Notable:** Won the OpenADMET-ExpansionRx blind challenge (Feb 2026), placing first among 370+ submissions with its Beacon models., Won the 2025 Polaris ADMET challenge - its first major competition victory., Achieved ~80% accuracy on novel chemotypes vs. ~30% for traditional approaches.

## Products & services

- **Beacon-1** — AI models trained on pre-competitive consortium data for real-world ADMET prediction with state-of-the-art accuracy, including on novel chemotypes.
- **Compass** — Software platform that lets chemists run virtual experiments, review predictions, and decide what compounds to synthesize in real time.
- **Indy** — An AI chemistry assistant that automates time-consuming operations and helps design and interpret experiments.
- **ADME-One** — Tier-1 ADME plus human PK projection offering launched with Ginkgo Datapoints and Tangible Scientific, bringing pharmacokinetic projection earlier into discovery.

## Achievements

- Won the OpenADMET-ExpansionRx blind challenge (Feb 2026), placing first among 370+ submissions with its Beacon models.
- Won the 2025 Polaris ADMET challenge - its first major competition victory.
- Achieved ~80% accuracy on novel chemotypes vs. ~30% for traditional approaches.
- Raised $29.3M total ($4.3M seed + $25M Series A).
- Received an up-to-$21M award to develop next-generation drug toxicity models and reduce reliance on animal testing.

## Latest updates

- **2026-02** — Beacon models won the OpenADMET-ExpansionRx blind challenge, beating 370+ submissions across pharma, biotech, academia and AI labs.
- **2025-05** — Closed a $25M Series A led by Obvious Ventures to expand AI model R&D and grow its pre-competitive data consortium.
- **2025** — Launched ADME-One with Ginkgo Datapoints and Tangible Scientific; received an up-to-$21M award for drug toxicity modeling.
- **2023** — Emerged from stealth with $4.3M seed funding co-led by a16z Bio + Health and Lux Capital.

## Links

- Website: https://www.inductive.bio
- LinkedIn: https://www.linkedin.com/company/inductive-bio
- Twitter/X: https://x.com/inductive_bio
- Bluesky: https://bsky.app/profile/inductivebio.bsky.social

---

Profile page: https://yespress.io/inductive-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-07